Clinical Trials Using Pemetrexed Disodium

Clinical trials are research studies that involve people. The clinical trials on this list are studying Pemetrexed Disodium. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-33 of 33

  • Heated Pemetrexed Disodium and Cisplatin during Surgery in Treating Participants with Pleural Malignant Mesothelioma

    This phase I trial studies the side effects and best dose of heated pemetrexed disodium when given together with heated cisplatin during surgeries such as extrapleural pneumonectomy or pleural decortication in treating participants with pleural malignant mesothelioma. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating pemetrexed disodium and cisplatin and infusing them directly into the chest during the surgery may kill more tumor cells.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Chemotherapy With or Without Porfimer Sodium-Based Photodynamic Therapy During Surgery in Treating Patients With Malignant Pleural Mesothelioma

    This randomized phase II trial studies how well chemotherapy with or without porfimer sodium-based photodynamic therapy during surgery works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of cancer, either by killing the cancer cells, by stopping them from dividing, or by stopping them from spreading. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. It is not yet known whether chemotherapy is more effective with or without porfimer sodium-based photodynamic therapy during surgery in treating patients with malignant pleural mesothelioma.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

    The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and / or overall survival compared with chemotherapy in patients with advanced lung cancer.
    Location: 2 locations

  • A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

    The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed / carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous Non-Small Cell Lung Cancer.
    Location: See Clinical Trials.gov

  • Pembrolizumab with or without Chemotherapy Before Surgery in Treating Patients with Stage I-IIIA Non-Small Cell Lung Cancer

    This phase II trial studies how well pembrolizumab with or without chemotherapy works when given before surgery in treating patients with stage I-IIIA non-small cell lung cancer. Immunotherapy with pembrolizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without chemotherapy may shrink the cancer prior to surgery and decrease the likelihood of the cancer returning following surgery.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Chemotherapy and Pembrolizumab in Treating Patients with Stage IV Non-small Lung Cancer Previously Treated with PD-1 or PD-L1 Inhibitor

    This phase II trial studies how well chemotherapy and pembrolizumab work in treating patients with stage IV non-small lung cancer previously treated with PD-1 or PD-L1 Inhibitor. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, or pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy and pembrolizumab may work better in controlling cancer and treating patients with non-small cell lung cancer.
    Location: 5 locations

  • Pembrolizumab in Treating Patients with Malignant Pleural Mesothelioma That Can Be Removed by Surgery

    This pilot phase I trial studies pembrolizumab in treating patients malignant pleural mesothelioma that can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)

    This expansion of the screening and multi-sub-study Lung-MAP trial is motivated by the changing landscape due to progress in the development of immunotherapies. The Lung-MAP trial was originally opened in June of 2014 for second-line treatment of participants with stage IV squamous lung cancer or squamous lung cancer that has come back (recurrent). The trial was amended to allow all participants with previously-treated stage IV or recurrent squamous lung cancer in 2015. The study is now expanding to allow participants with all types of previously-treated stage IV or recurrent non-small cell lung cancer. The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned in order to compare new targeted cancer therapy designed to block the growth and spread of cancer, with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes “non-match” sub-studies which will include all screened participants not eligible for any of the biomarker-driven sub-studies.
    Location: 681 locations